Opportunity Information: Apply for 72065622RFA00004
USAID Malaria Capacity Strengthening (MCAPS) in Mozambique is a USAID/Mozambique grant opportunity to fund a five-year Cooperative Agreement valued at up to USD 29.9 million, covering the period from 2022 through 2027. The overall goal is to strengthen malaria service delivery in selected target provinces by improving the quality and consistency of malaria prevention, diagnosis, and treatment services delivered both in health facilities and at the community level. The activity is designed to directly support Mozambique's National Malaria Control Program (NMCP) and align with its stated objective of testing 100 percent of suspected malaria cases and treating 100 percent of confirmed cases, emphasizing complete case management coverage wherever patients seek care.
Beyond routine diagnosis and treatment, the opportunity also highlights two additional priority areas: malaria in pregnancy (MiP) and stronger surveillance, monitoring, and evaluation (often shortened in the notice as SME). This means the funded activity is expected not only to improve frontline clinical and community practices, but also to reinforce the systems that track malaria trends, measure program performance, and support data-driven decision-making. In practical terms, this kind of scope typically involves strengthening provider and community health worker capacity, improving adherence to national guidelines, enhancing the quality of reporting and use of surveillance data, and supporting NMCP efforts to ensure pregnant women receive appropriate malaria prevention and care services.
Administratively, the opportunity is issued as a continuation category funding notice under the health sector (CFDA 98.001) and is open to unrestricted applicants, meaning there are no special eligibility constraints listed in the posting beyond standard USAID requirements. The funding opportunity number is 72065622RFA00004, released by USAID in Maputo, Mozambique, with an award ceiling of USD 29.9 million. An amendment (Amendment No. 1) was issued to update and clarify the solicitation package. The amendment extended the application deadline from February 14, 2022 at 9:00 a.m. to February 28, 2022 at 5:00 p.m., and it also included a set of questions and answers from prospective applicants to address common points of confusion. In addition, the amendment provided the SF-424A budget information form and a revised version of the Request for Applications (RFA), labeled as Revision I, with changes highlighted so applicants could quickly identify what had been updated.
Taken together, MCAPS is framed as a sizable, multi-year partnership mechanism where USAID and the recipient work collaboratively (as is typical under a Cooperative Agreement) to strengthen Mozambique's malaria response. The emphasis is not just on delivering services, but on improving service quality, ensuring complete testing and treatment coverage, improving malaria-related care for pregnant women, and building a stronger surveillance and performance monitoring foundation that can sustain progress over the life of the award and beyond.Apply for 72065622RFA00004
- The Mozambique USAID-Maputo in the health sector is offering a public funding opportunity titled "USAID Malaria Capacity Strengthening (MCAPS) in Mozambique" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 98.001.
- This funding opportunity was created on 2022-01-13.
- Applicants must submit their applications by 2022-02-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $29,900,000.00 in funding.
- Eligible applicants include: Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: USAID Malaria Capacity Strengthening (MCAPS) in Mozambique
What is the USAID MCAPS opportunity in Mozambique?
USAID Malaria Capacity Strengthening (MCAPS) in Mozambique is a USAID/Mozambique grant opportunity to fund a five-year Cooperative Agreement focused on strengthening malaria service delivery in selected target provinces.
What is the overall goal of MCAPS?
The overall goal is to strengthen malaria service delivery by improving the quality and consistency of malaria prevention, diagnosis, and treatment services delivered both in health facilities and at the community level.
What kind of award mechanism is MCAPS?
The opportunity is structured as a Cooperative Agreement, which is described as a collaborative partnership mechanism where USAID and the recipient work together over the life of the award.
How long is the MCAPS award period?
The activity covers a five-year period from 2022 through 2027.
What is the maximum funding amount available under this opportunity?
The award ceiling is up to USD 29.9 million.
Which organization and country mission is issuing this opportunity?
The opportunity is issued by USAID/Mozambique, with the posting referencing USAID in Maputo, Mozambique.
What is the funding opportunity number for MCAPS?
The funding opportunity number is 72065622RFA00004.
What sector and CFDA number does this opportunity fall under?
The notice places the opportunity under the health sector and references CFDA 98.001.
Who is eligible to apply?
The posting states the opportunity is open to unrestricted applicants, meaning no special eligibility constraints are listed beyond standard USAID requirements.
What does MCAPS aim to improve at the health facility level and community level?
MCAPS is intended to improve the quality and consistency of malaria prevention, diagnosis, and treatment services in health facilities and within community-based service delivery.
How does MCAPS align with Mozambique's National Malaria Control Program (NMCP)?
The activity is designed to directly support Mozambique's NMCP and align with the NMCP objective of testing 100 percent of suspected malaria cases and treating 100 percent of confirmed cases.
What does "complete case management coverage" mean in the context of this opportunity?
In this notice, the emphasis is on reaching complete coverage for testing and treatment wherever patients seek care, consistent with testing all suspected cases and treating all confirmed cases.
Does the scope focus only on routine malaria diagnosis and treatment?
No. In addition to routine diagnosis and treatment, the opportunity highlights two additional priority areas: malaria in pregnancy (MiP) and stronger surveillance, monitoring, and evaluation (SME).
What is malaria in pregnancy (MiP) and how is it treated in the scope?
The opportunity identifies MiP as a priority area and indicates the funded activity is expected to support NMCP efforts to ensure pregnant women receive appropriate malaria prevention and care services.
What does SME stand for in this opportunity?
SME is used in the notice to refer to surveillance, monitoring, and evaluation.
Why are surveillance, monitoring, and evaluation (SME) emphasized?
The scope includes reinforcing systems that track malaria trends, measure program performance, and support data-driven decision-making, alongside improvements to frontline service delivery.
What types of systems-strengthening work are implied by the scope?
Based on the description, the scope typically involves strengthening provider and community health worker capacity, improving adherence to national guidelines, enhancing the quality of reporting and the use of surveillance data, and supporting NMCP efforts related to MiP services.
Is this a new solicitation or a continuation category funding notice?
The opportunity is issued as a continuation category funding notice under the health sector.
Was the solicitation amended after release?
Yes. Amendment No. 1 was issued to update and clarify the solicitation package.
What changed under Amendment No. 1?
The amendment extended the application deadline, included a set of questions and answers from prospective applicants, and provided the SF-424A budget information form along with a revised Request for Applications (Revision I) with changes highlighted.
What was the original application deadline, and what was the extended deadline?
The deadline was extended from February 14, 2022 at 9:00 a.m. to February 28, 2022 at 5:00 p.m.
What is the purpose of the Q&A included in the amendment?
The amendment notes that it included questions and answers from prospective applicants to address common points of confusion.
What is SF-424A and how is it referenced here?
SF-424A is referenced as the budget information form provided as part of the amendment package.
What is "Revision I" of the RFA?
Revision I refers to the revised version of the Request for Applications included with the amendment, with changes highlighted to help applicants identify updates.
What is USAID ultimately trying to achieve through MCAPS?
MCAPS is framed as a multi-year partnership to strengthen Mozambique's malaria response by improving service quality, ensuring complete testing and treatment coverage, improving malaria-related care for pregnant women, and building stronger surveillance and performance monitoring foundations that can sustain progress beyond the award period.
Browse more opportunities from the same category: Health
Next opportunity: Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
Previous opportunity: Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for 72065622RFA00004
Applicants also applied for:
Applicants who have applied for this opportunity (72065622RFA00004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U01 Clinical Trial Not Allowed) Apply for RFA AI 22 002 Funding Number: RFA AI 22 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 22 110 Funding Number: RFA MH 22 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U19 Clinical Trial Not Allowed) Apply for RFA AI 22 003 Funding Number: RFA AI 22 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed) Apply for RFA TR 22 012 Funding Number: RFA TR 22 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed) Apply for RFA MH 22 111 Funding Number: RFA MH 22 111 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) Apply for PAR 22 102 Funding Number: PAR 22 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) Apply for PAR 22 075 Funding Number: PAR 22 075 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional) Apply for RFA MD 22 007 Funding Number: RFA MD 22 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed) Apply for RFA HG 22 004 Funding Number: RFA HG 22 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) Apply for PAR 22 103 Funding Number: PAR 22 103 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed) Apply for RFA HL 23 002 Funding Number: RFA HL 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed) Apply for RFA HL 23 001 Funding Number: RFA HL 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) Apply for RFA HL 23 011 Funding Number: RFA HL 23 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) Apply for RFA HL 23 010 Funding Number: RFA HL 23 010 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| NIMH Instrumentation Program (S10 Clinical Trial Not Allowed) Apply for RFA MH 22 155 Funding Number: RFA MH 22 155 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) Apply for RFA HL 23 012 Funding Number: RFA HL 23 012 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional) Apply for PAR 22 113 Funding Number: PAR 22 113 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required) Apply for PAR 22 112 Funding Number: PAR 22 112 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| NHGRI Short Courses for Genomics-Related Research Education (R25 Clinical Trial Not Allowed) Apply for PAR 22 095 Funding Number: PAR 22 095 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Strategic Project for Epidemic Control of Key Populations Apply for RFI 674 21 KEYPOPBOTSWANA Funding Number: RFI 674 21 KEYPOPBOTSWANA Agency: South Africa USAID-Pretoria Category: Health Funding Amount: $15,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "72065622RFA00004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.